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Introduction
Cerebral cavernous malformation (CCM) is a common cere-
brovascular anomaly, affecting 1 in 200 individuals and 
predisposing patients to a lifetime risk of seizures, hemor-
rhagic stoke, and other neurological deficits (Leblanc et al., 
2009; Faurobert and Albiges-Rizo, 2010). Heterozygous loss 
of KRIT1 (also known as CCM1) causes a familial form of 
CCM (Laberge-le Couteulx et al., 1999; Sahoo et al., 1999), 
characterized by the development of multiple vascular dyspla-
sias within the brain but also in the spinal cord, retina, and 
skin (Leblanc et al., 2009; Faurobert and Albiges-Rizo, 2010). 
A similar disease is associated with heterozygosity for loss of 
function of CCM2 or CCM3, and these three proteins interact 
with each other (Leblanc et al., 2009; Faurobert and Albiges-
Rizo, 2010). CCM lesions typically arise in adulthood and con-
sist of beds of dilated capillary vessels with little intervening 
brain tissue. There is a reduction in endothelial cell (EC)–cell 
adhesion within lesions but not in the surrounding normal brain 
tissue (Leblanc et al., 2009; Faurobert and Albiges-Rizo, 2010). 
Loss of KRIT1 leads to defects in EC junctional integrity 
(Glading et al., 2007) associated with increased RhoA activity 
(Stockton et al., 2010) and apicobasal polarity (Lampugnani 
et al., 2010), and loss of CCM1 similarly disrupts EC–cell 
junctions (Glading and Ginsberg, 2010). Inhibiting the Rho 
effector, Rho kinase, reverses the effect of KRIT1 silencing 
on EC junctions (Stockton et al., 2010) and slows the devel-
opment and progression of CCMs in a murine model of the 
human disease (McDonald et al., 2012).
In mice, deletion of Krit1 leads to early embryonic 
lethality (approximately embryonic day 10 [E10]) caused by 
gross defects in multiple vascular beds (Whitehead et al., 
2004). Endothelial-specific deletion of Krit1 early in life 
produces hemorrhagic vascular lesions in the cerebellum 
and retina that resemble CCMs (Boulday et al., 2011). Com-
bined with the more global effect of the constitutive deletion, 
these data suggest that KRIT1 functions in multiple endothe-
lial beds but at only specific developmental times. Constitutive 
global or endothelial-specific deletion of CCM2 produces 
virtually identical phenotypes to those of KRIT1 (Kleaveland 
et al., 2009; Whitehead et al., 2009). Similarly, in zebrafish, 
loss of krit1, ccm2, or heg (heart of glass) function leads 
to aberrant vascular morphogenesis (Hogan et al., 2008) and 
The products of genes that cause cerebral cavernous malformations (CCM1/KRIT1, CCM2, and CCM3) physically interact. CCM1/KRIT1 links this complex to 
endothelial cell (EC) junctions and maintains junctional in-
tegrity in part by inhibiting RhoA. Heart of glass (HEG1), a 
transmembrane protein, associates with KRIT1. In this paper, 
we show that the KRIT1 band 4.1, ezrin, radixin, and moesin 
(FERM) domain bound the HEG1 C terminus (Kd = 1.2 µM) 
and solved the structure of this assembly. The KRIT1 F1 and 
F3 subdomain interface formed a hydrophobic groove that 
binds HEG1(Tyr1,380-Phe1,381), thus defining a new mode of 
FERM domain–membrane protein interaction. This structure 
enabled design of KRIT1(L717,721A), which exhibited a 
>100-fold reduction in HEG1 affinity. Although well folded 
and expressed, KRIT1(L717,721A) failed to target to EC 
junctions or complement the effects of KRIT1 depletion on 
zebrafish cardiovascular development or Rho kinase acti-
vation in EC. These data establish that this novel FERM–
membrane protein interaction anchors CCM1/KRIT1 at EC 
junctions to support cardiovascular development.
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cardiac dilatation (Mably et al., 2003, 2006), and the vascular 
phenotypes in HEG1- and KRIT1-deficient mice are similar 
(Kleaveland et al., 2009). Therefore, KRIT1, CCM2, and HEG1 
interact physically and genetically and play major roles in regu-
lating vascular development and integrity.
KRIT1 contains a C-terminal band 4.1, ezrin, radixin, 
and moesin (FERM) domain and a series of N-terminal an-
kyrin repeats (Sahoo et al., 2001). FERM domains are com-
prised of F1, F2, and F3 subdomains (Fehon et al., 2010). 
KRIT1 FERM domain localizes KRIT1 to EC–cell junctions 
(Glading et al., 2007), and KRIT1 is required for the junc-
tional localization of its binding partner, CCM2 (Stockton 
et al., 2010). KRIT1 F1 subdomain binds Rap1 in a GTP-
 dependent manner, and KRIT1–Rap1 interaction is important 
for KRIT1 localization in EC junctions and KRIT1 function 
(Liu et al., 2011). KRIT1 FERM F3 subdomain is predicted 
to comprise a phosphotyrosine-binding (PTB) domain. Many 
proteins bind to membrane proteins via their FERM domains. 
In cases in which structural data are available, the membrane 
protein cytoplasmic domain interacts with the F3 subdomain 
(Calderwood, 2004; Fehon et al., 2010). Here, we use pro-
tein crystallography to determine the structural basis of the 
KRIT1–HEG1 interaction. Surprisingly, the interaction dif-
fered from well-characterized FERM domain–membrane 
protein interactions (Calderwood, 2004; Anthis et al., 2009; 
Fehon et al., 2010) in which the F3 subdomain alone pro-
vides a binding site. Instead, the HEG1 binding interface 
was localized in a hydrophobic groove between the F1 and 
F3 subdomains of KRIT1. The biochemical relevance of this 
structure was validated by structure-based mutants of HEG1 
or KRIT1 that disrupted their interaction; the biological rele-
vance of the interaction was established by showing that 
KRIT1 mutants with reduced binding to HEG1, failed to lo-
calize to EC–cell junctions, and did not support cardiovascular 
development in zebrafish. These data reveal the structural 
basis of anchoring of KRIT1, the central scaffold of the CCM 
complex, to cell–cell junctions via HEG1, and establish the 
biological importance of this new form of FERM domain–
membrane protein interaction.
Results and discussion
Defining the KRIT1–HEG1 interaction
The HEG1 cytoplasmic tail interacts with KRIT1 protein in 
the complex milieu of mammalian cell lysates (Kleaveland 
et al., 2009). To test whether HEG1–KRIT1 is a direct protein–
protein interaction, we purified recombinant GST-fused KRIT1 
FERM domain and HEG1 cytoplasmic tail (residues 1,274–
1,381) proteins and found that HEG1 tail bound directly to the 
KRIT1 FERM (F123) protein (Fig. 1 A). Homology models of 
the KRIT1 FERM domain (Francalanci et al., 2009; Liu et al., 
2011) predicted that the F3 subdomain of the FERM domain 
has a PTB domain fold. HEG1 C terminus contains a highly 
conserved NPxY/F sequence, which in many cases is able to 
interact with PTB-containing proteins (Smith et al., 2006); 
however, we found that although the C-terminal 26 residues 
Figure 1. The direct interaction of KRIT1–HEG1. (A) HEG1 cytoplasmic 
tail model protein (residues 1,274–1,381) binds to recombinant GST-
KRIT1 FERM but not GST alone. Integrin IIb model protein does not bind 
to KRIT1 F123. Coomassie blue–stained SDS-PAGE gels are representative 
of three experiments. All lanes were from the same gel. (B) HEG1, HEG1 
(N1367A/F1370A), HEG1 C26, and HEG1 C26 (N1367A/F1370A) 
tail model proteins bind to recombinant GFP-KRIT1 F123 from HEK293 
cell lysates. HEG1 1,363 truncated tail model protein binds to KRIT1 
F123 to a much lesser extent. Top section shows the sequence of HEG1 
cytoplasmic tail and indicates the mutated residues. All lanes were from 
the same membrane. Bold letters refer to the mutated sequence. (C) Calo-
rimetric titration of 600 µM HEG1 peptide, out of the syringe, into 40 µM 
KRIT1 FERM domain in the sample cell (Kd = 1.2 µM). The top line defines 
the background. The bottom line defines the data fitting.
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HEG1–KRIT1 binding interface
The HEG1–KRIT1 interaction buried 640 Å2 of the HEG1 
(residues 1,356–1,381) surface; the HEG1 binding pocket com-
pletely buried the C-terminal aromatic residues of HEG1, i.e., 
Tyr1,380 and Phe1,381 (Fig. 2, C and D, yellow), which accounts 
for 64% of the HEG1 buried area. The N-terminal region of 
the peptide comes out of the pocket making relatively few con-
tacts with KRIT1 (Fig. 2 B). The HEG1 Asp1,379 side chain does 
not make direct hydrogen bonds with any of the three sur-
rounding basic residues Lys475, Lys720, and Lys724 from KRIT1 
(Fig. 2 C). However, those three lysine residues with Arg513 
form a distinct cave with a positively charged entrance (Fig. 2 D, 
bottom section). In contrast, the surface of KRIT1 helix 2A is 
negatively charged because of the presence of Asp486, Glu489, 
and Glu493 and shows a good charge complementarity with 
HEG1 Arg1,378 (Fig. 2 D, top region). The N-terminal HEG1 
residues, S1,375RR1,377, make little contact with KRIT1 and 
account for 10% of the buried surface, whereas no electron 
density is observed for the 19 N-terminal residues. Thus the 
structure of the HEG1–KRIT1 complex indicates that the 
of HEG1 (HEG1 C26) were sufficient for KRIT1 binding, 
the NPxY/F motif was dispensable. Mutating the N1,367PSF1,370 
sequence to A1,367PSA1,370 (HEG1 NAFA and HEG1 C26 NAFA 
mutants) had no effect on KRIT1 binding (Fig. 1 B). In contrast, 
removal of 19 residues 1,363–1,381 at the C terminus of HEG1 
(HEG1 1,363) drastically reduced KRIT1 binding, suggest-
ing that the key determinant is the C-terminal 19 residues of HEG. 
Isothermal titration calorimetry (ITC; Fig. 1 C and Table 1) 
revealed that the KRIT1 FERM domain bound to HEG1 C26 
with Kd = 1.2 ± 0.14 µM. Thus, the HEG1 C-terminal 19 residues 
are the principal binding site for the KRIT1 FERM domain, 
and the N1,367PSF1,370 motif is dispensable for this interaction.
Structure of the KRIT1–HEG1 complex
The human KRIT1 FERM domain, KRIT1(417–736), was 
purified and crystallized with a recombinant human HEG1 
peptide containing the 26 C-terminal residues. The structure 
(Protein Data Bank accession no. 3U7D) was solved and re-
fined to a 2.5-Å resolution with an Rwork of 23.4% and Rfree of 
30.9% (Table 2). The current KRIT1 model excludes residues 
647–652 in the 1C–2C loop, which are poorly defined 
in the electron density map (Fig. 2, A and B). Each asym-
metric unit contained two KRIT1–HEG1 complexes that are 
almost identical, root-mean-square deviation = 0.6 Å, with 
distinct electron density visible for the C-terminal seven resi-
dues of the HEG1 tail. The last three residues (D1,379YF1,381) 
showed the best electron density (Fig. 3 A), whereas the 
first 19 residues were not observed, suggesting that they re-
mained unstructured.
The KRIT1 FERM domain is similar to that found in 
ERM proteins and contains three subdomains arranged as a 
cloverleaf (Fig. 2 B): F1 (residues 420–510; Fig. 2 B, green 
and blue), F2 (residues 516–630; Fig. 2 B, red), and F3 (residues 
638–730; Fig. 2 B, orange). The F1 domain has an ubiquitin-
like fold (DALI server Z score = 7.1, root-mean-square devi-
ation = 2.1 Å, Protein Data Bank no. 3NOB), although it has 
a novel helix 2A inserted in the 4A–5A loop (residues 
480–494; Fig. 2, A and B, blue helix). This helix, which is 
not observed in other ubiquitin-like folds, is kinked by 70° 
in the middle because of the presence of Pro488 breaking the 
hydrogen bond network (Fig. 3 B). It is, however, kept into 
position by extensive hydrophobic contacts between Trp487 
and residues from the 3A to 5A strands. The F2 domain 
contains a core four-helix equivalent to that found in acyl-CoA–
binding protein, and the F3 domain shares a fold of an ada-
ptable ligand module seen for PTB, pleckstrin homology, 
and EHV1 (Enabled/ Vasodilator-stimulated phosphoprotein 
homology) domains.
Table 1. Thermodynamic parameters for binding of KRIT1 FERM domain to HEG1 cytoplasmic tail
Clone n Kd H° G° TS°
 µM Kcal/mol Kcal/mol Kcal/mol
Wild-type 1.01 1.2 ± 0.14 10.0 8.1 1.9
Kd = 1 / Ka . G° = RTlnKa. G = H  TS. Ka, association constant; H, enthalpy changes; G, Gibbs energy changes; R, gas constant; T, absolute temperature; 
S, entropy changes.
Table 2. Data collection and refinement statistics for the KRIT1 
FERM domain in complex with the HEG1 cytoplasmic tail
Crystallographic statistic Complex (3U7D)
Data collection
Space group P21
Cell dimensions:
a, b, c (Å) 73.1, 76.8, 79.2
, ,  (°) 90.0, 113.6, 90.0
Resolution (Å) 52.7-2.49 (2.62-2.49)
Rmerge 5.8 (31.2)
I/I 5.3 (2.3)
Completeness (%) 98.7 (97.9)
Redundancy 2.2 (2.2)
Refinement
Resolution (Å) 72.6-2.49
No. of reflections 26,420
Rwork/Rfree 23.4/30.9
No. of atoms 5,136
Protein 5,126
Water 10
B factors 50.3
Protein 50.3
Water 35.0
R.m.s. deviations:
Bond lengths (Å) 0.017
Bond angles (°) 1.746
R.m.s., root-mean-square. Highest resolution shell is shown in parentheses.
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pocket (Fig. 2 B). The KRIT1 4A–2A loop mainly interacts 
by hydrogen bonding with the HEG1 sequence (Fig. 3 A, left 
section), in which the backbone carbonyl group of KRIT1 Gln473 
bonds to the backbone amide of HEG1 Phe1,381, and KRIT1 
Lys475 side chain hydrogen bond to the backbone carbonyl of 
HEG1 Asp1,379. KRIT1 helix 2A forms a hydrophobic pocket 
C-terminal Tyr-Phe dipeptide of HEG1 is the dominant determi-
nant of this high affinity interaction.
Binding of the HEG1 sequence occurs at the KRIT1 F1 
and F3 interface mainly through three contacted regions: (1) 
polar contacts in the 4A–2A loop, (2) a hydrophobic area on 
helix 1C, and (3) the novel helix 2A closing the binding 
Figure 2. Crystal structure of the KRIT1 FERM domain bound to the HEG1 cytoplasmic tail peptide reveals a new mode of binding. (A) Sequence of human 
KRIT1 (UniProt O00522) FERM domain with secondary structure elements shown below the sequence. (B) View of the KRIT1 FERM domain bound to the 
HEG1 peptide. The HEG1 peptide is shown in yellow. The KRIT1 FERM domain consists of three subdomains: F1 (green and blue), F2, and F3. The linkers 
F1–F2 (residues 511–515) and F2–F3 (residues 631–637) are colored in gray, and the new features of the F1 domain that are not present in ubiquitin and 
radixin are shown in blue, i.e., helix 2A (residues 480–494). (C) The HEG1 binding pocket at the KRIT1 F1 and F3 interface. The interaction is mainly 
formed by hydrogen bonds from residues in loop 4A–2A and hydrophobic residues from helix 2A and 1C. (D) Surface electrostatic potentials of the 
KRIT1 FERM domain with the HEG1 peptide shown as a stick model. The HEG1 residues buried in the hydrophobic pocket are shown in yellow, whereas 
the charged residues exiting the pocket are shown in white.
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(Fig. 3 B), composed of Ile490 and Leu494, with Leu472 from the 4A 
strand to accommodate the aromatic ring of HEG1 Tyr1,380. The 
HEG1 Tyr1,380 hydroxyl group is stabilized by hydrogen bonding 
with one of the indole nitrogens of KRIT1 His483 (Fig. 3 A). The 
F3 domain contributes to the interaction mainly from KRIT1 
residues Leu717 and Leu721 of helix 1C completing the hydro-
phobic pocket surrounding the HEG1 C-terminal Tyr1,380 and 
Phe1,381 residues (Fig. 3 A). This structure represents a new mode 
of interaction of a FERM domain with a transmembrane protein 
and reveals the basis of the high affinity interaction of HEG1 with 
KRIT1. Furthermore, it differs from the classical PTB domain–
peptide interaction (Smith et al., 2006) and explains the lack of 
dependence of the interaction on the HEG1 NPSF motif.
To test whether the HEG1 C-terminal aromatic dipeptide 
is required for binding to KRIT1, we formed an affinity matrix 
with an immobilized synthetic HEG1 C-terminal 19-residue 
peptide (HEG1-C19) or a truncated HEG1 peptide lacking the 
two C-terminal residues (HEG1-C19delYF). HEG1-C19 bound 
to KRIT1 FERM domain whereas, HEG1-C19delYF exhibited a 
>20-fold reduction in binding (Fig. 4 A). Thus, the C-terminal 
Tyr-Phe dipeptide is critical for HEG1–KRIT1 interaction.
The biological role of the  
KRIT1–HEG1 interaction
The structure described in this study created the opportunity to 
examine the functional importance of the KRIT1–HEG1 inter-
action. Specifically, KRIT1 Leu717 and Leu721 help establish the 
hydrophobic pocket that buries the C terminus of HEG1. In con-
sequence, a KRIT1(L717,721A) mutant exhibited markedly re-
duced binding to the HEG1-C19 peptide as judged by affinity 
chromatography (Fig. 4 B). Furthermore, injection of 2.2 mM 
HEG1 peptide into a solution of 40 µM KRIT1(L717,721A) 
FERM protein did not generate significant heat in an ITC ex-
periment, indicating a >100-fold reduction in affinity (unpub-
lished data). KRIT1(L717,721A) FERM protein was well folded 
as judged by its sharp melting temperature of 49.5°C in dif-
ferential scanning calorimetry (Fig. S1 A). Furthermore, we 
made the corresponding mutant in the full-length human and 
zebrafish KRIT1 (krit1(L714,718A)), and both proteins were 
well-expressed in HEK293 cells (Fig. S1, B and C). KRIT1 has 
other important binding partners, including CCM2 (Zawistowski 
et al., 2005) and Rap1 (Serebriiskii et al., 1997). KRIT1(L717,721A) 
mutant interacted with both CCM2 (Fig. 4 C) and Rap 1 (Fig. 4 D) 
to the same extent as the wild-type (WT) protein. Thus, the 
KRIT1(L717,721A) is well folded and expressed, exhibits mark-
edly reduced affinity for HEG1, but maintains interactions with 
other known binding partners of KRIT1.
HEG1 is a transmembrane receptor that localizes at EC–cell 
junctions (Kleaveland et al., 2009) and may therefore interact 
with KRIT1 to localize KRIT1 to junctions. In human umbilical 
vein ECs (HUVECs), KRIT1 localized at EC–cell junctions 
(Fig. 4 E, top), whereas KRIT1(L717,721A) did not (Fig. 4 E, 
bottom). KRIT1(L717,721A) junctional localization was not 
restored by stabilization of junctions by inhibition of Rho kinase 
(Fig. S2). Both WT and mutant KRIT1 also exhibited nuclear 
and cytoplasmic localizations as previously reported (Glading 
et al., 2007).
Figure 3. Structural details of the HEG1 binding pocket in KRIT1.  
(A) Electron density of the HEG1 peptide in complex with the KRIT1 FERM 
domain. Electron density (2 Fo-Fc map contoured at 1.2 ) of the HEG1 
peptide. The HEG1 peptide is colored as in Fig. 2 C, and the KRIT1 
FERM domain is as in Fig. 2 B. Some of the key KRIT1 residues are high-
lighted. (B) Close view of the novel helix 2A in the KRIT1 F1 domain. 
The helix is kinked by 70° in the middle because of the presence of 
Pro488. The helix position is stabilized by hydrophobic contacts with 
residues from the  sheet. (C) The surface charge map of the KRIT1 
FERM domain shows a basic surface at the F1–F2–F3 subdomain inter-
face. The position of Arg452 is highlighted as mutation of this residue 
to Glu reduces KRIT1 binding to Rap1.
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Figure 4. Reduced binding of KRIT1 (L717,721A) to HEG1. (A) HEG1 C19 cytoplasmic tail model protein binds to recombinant GFP-KRIT1 FERM from 
HEK293 cell lysates. HEG1 C19delYF, which lacks the last two residues, does not bind to GFP-KRIT1 FERM. (bottom) The equal loading of tail proteins as 
judged by SDS-PAGE and Coomassie blue staining. Blots are representative of three experiments. (B) HEG1 C19 tail model protein binds to recombinant 
GFP-KRIT1 FERM from HEK293 cell lysates but not GFP-KRIT1 FERM(L717,L721A). Both WT and mutant proteins are expressed at similar levels. All lanes 
were from the same gel. (C) Both GFP-fused KRIT1 WT and GFP-fused KRIT1(L717,721A) are associated with CCM2 at equivalent levels as assessed 
by coimmunoprecipitation and immunoblotting. All lanes were from the same gel. (D) Both GST-KRIT1 F123 and GST-KRIT1 F123(L717,721A) bind to 
HA-Rap1V12 from HEK293 cell lysates. GST-KRIT1 F123(R452E) mutant serves as a negative control as it does not bind to Rap1. (E) HA-tagged KRIT1 
WT colocalizes with VE-cadherin at HUVEC cell–cell junctions. In contrast, HA-KRIT1(L717,L721A) does not . HA-KRIT1, green. VE-cadherin, red. 
IP, immunoprecipitation; LALA, KRIT1(L717A,L721A). Bar, 50 µm.
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embryos at the one-cell stage and assessed cardiac dilation 
at 48 h postfertilization (hpf) as previously described (Liu 
et al., 2011). Injecting San MO alone resulted in heart dila-
tion in 95% of zebrafish embryos. Authentic dilation was 
verified by identifying the endocardium in the fluorescence 
images of flk1:EGFP zebrafish (Fig. 5 A). Coinjection of 
WT krti1 cRNA together with San MO resulted in 80% 
reversal of the dilated heart phenotype (Fig. 5 B). In sharp 
contrast, coinjection of krit1(L714,718A) cRNA resulted in 
The KRIT1–HEG1 interaction is important 
for cardiovascular development and  
Rho signaling in ECs
Zebrafish embryos lacking heg or krit1 (also known as santa 
[San]) exhibit a similar dilated heart phenotype (Mably et al., 
2003, 2006). To test whether the HEG1–KRIT1 interaction 
is important in zebrafish heart development, we coinjected 
krit1 WT or krit1(L714,718A) (the orthologue of human KRIT1 
(L717,721A)) cRNAs and San morpholino (MO) into zebrafish 
Figure 5. KRIT1–HEG1 interaction is required for normal zebrafish cardiovascular development and inhibition of RhoA/Rho kinase in EC. (A) Flk1:EGFP 
transgenic krit1-morphant (San MO) embryo showed enlarged heart phenotype. Coinjecting the cRNA encoding HA-tagged wild-type (WT) zebrafish 
krit1 protein reduced the heart size of injected fish, whereas fish coinjected with cRNA encoding HA-tagged Krit1 (L714,L718A), orthologous to human 
KRIT1(L717,L721A) mutant still exhibited a dilated heart phenotype. Dilated heart phenotype was scored by cardiac dilation in living fish. Authentic dila-
tion was verified by indentifying the endocardium in the fluorescence images, which is indicated by the dotted lines. All microscopic images were taken 
at 48 hpf. Bars, 500 µm. (B) Bar graphs showing effects of Krit1 (L714,718A) mutant on zebrafish cardiovascular development. Data are expressed as 
number of embryos without dilated heart phenotype divided by total number of embryos used per experiment × 100; means ± SD. *, P < 0.05 compared 
with San MO + HA-WT cRNA group. Data are from three independent experiments. Total number of animals used: 94 in San MO + HA-WT group and 
71 in San MO + HA-Krit1(L714,718A) group. (C) Both HA-tagged zebrafish Krit1 WT and Krit1(L714,718A) proteins were expressed at similar levels in 
injected embryos as revealed by immunoprecipitation with a rabbit anti-HA antibody from zebrafish embryo lysates and immunoblotting with a mouse anti-
HA antibody. (D) Effect of disruption of the HEG1–KRIT1 interaction on RhoA/Rho kinase signaling in EC. Silencing of KRIT1 caused a marked increase 
in myosin light chain phosphorylation that was not reversed by expression of KRIT1 (L717,721A). (E) Extent of KRIT1 depletion and reconstitution in the 
experiment depicted in D. IP, immunoprecipitation; LALA, KRIT1(L717A,L721A); MLC myosin light chain.
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KRIT1 FERM domain as the antigen as previously described (Liu et al., 2011). 
Anti-KRIT1 15B2 antibody was used for immunoprecipitation. Anti-KRIT1 
6832 antibody was used for immunoblotting at 1:1,000. Polyclonal 
anti-GFP antibody (Takara Bio Inc.) was used for immunoprecipitation. 
Monoclonal anti-GFP antibody (Takara Bio Inc.) was used for immuno-
blotting at 1:5,000.
Human KRIT1 cDNAs encoding HA-, GFP-, and GST-tagged full-length 
KRIT1 and KRIT1 FERM domain were previously described (Liu et al., 2011). 
In brief, HA-, GFP-, and GST-tagged constructs were cloned in pcDNA3.1() 
(Invitrogen), pEGFP-C1 (Takara Bio Inc.), and pGEX2TK vectors, respectively. 
Human KRIT1(L717,721A) mutant was generated by site-directed muta-
genesis using the site-directed mutagenesis kit (QuikChange; Agilent Tech-
nologies). The mutant was then subcloned into pGEX2TK (GE Healthcare), 
pcDNA3.1 (Invitrogen), and pEGFP-C1 (Takara Bio Inc.) vectors for express-
ing GST-, HA-, and GFP-tagged proteins, respectively. Zebrafish krit1 cDNA 
was a gift from B. Weinstein (National Institutes of Health, Bethesda, MD) 
and subcloned into pcDNA3.1 vector with an N-terminal HA tag as previ-
ously described (Liu et al., 2011). Zebrafish krit1 (L714,718A) mutant was 
generated using the QuikChange site-directed mutagenesis kit. pRK5-CCM2 
encoding FLAG-tagged human CCM2 has been previously described and 
was the gift of D. Marchuk (Duke University, Durham, NC; Zawistowski et al., 
2005). pMT2-HA-Rap1A(G12V) was a gift from J. Bos (University Medical 
Center Utrecht, Utrecht, Netherlands) as previously described (Liu et al., 
2011). The recombinant human HEG1 cytoplasmic tail model protein 
affinity matrix was previously described (Liu et al., 2011). HEG1 tail trun-
cation mutants, C-26 and C-19, were generated by PCR from the HEG1 
full-length tail construct and subcloned into the same pHisAvi vector. HEG1 
tail (N1367A,F1370A) mutant was generated using the QuikChange 
site-directed mutagenesis kit.
In vitro protein interaction assay
Bacterial expression plasmids encoding GST-KRIT1 FERM or GST vector 
were expressed in BL21 (DE3) (EMD Millipore), and recombinant proteins 
were purified using glutathione–Sepharose beads according to manufac-
turer’s instructions (GE Healthcare). HEG1 and IIb intracellular tail model 
proteins were prepared as previously described (Pfaff et al., 1998). 
In brief, His6-tagged HEG1 and IIb intracellular tails containing an in vivo 
biotinylation peptide tag at the N terminus were cloned into pET15b. Tail 
proteins were expressed and purified from Escherichia coli. Pull-down assay 
using cell lysates were previously described (Liu et al., 2011). In brief, 
HEK293 cells were transfected with the indicated cDNAs. 24 h after trans-
fection, cells were lysed in cold lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 0.5% NP-40, and 5 mM MgCl2) plus protease inhibitor cocktail 
(Roche). A total of 10 µg of immobilized bead-bound proteins was added 
to 350 µg of clarified cell lysates. Reactions were kept at 4°C overnight. 
After washing the beads with lysis buffer, samples were fractioned on 4–20% 
SDS-PAGE gel (Invitrogen). Bound proteins were analyzed by immunoblotting 
or Coomassie blue staining.
Immunoprecipitation
HEK293 cells were transfected with indicated cDNAs and incubated for 
24 h. Cells were scraped on ice in lysis buffer plus protease inhibitor cock-
tails (Roche). A total of 2 µg monoclonal anti-GFP antibody was added to 
350 µg cell lysates and incubated at 4°C overnight. Protein G–Sepharose 
(Invitrogen) was added to the reaction mixture and further incubated for 4 h 
at 4°C. After three washes with lysis buffer, beads were mixed with sample 
buffer and subjected to SDS-PAGE. Immunoprecipitated proteins were 
detected by immunoblotting.
ITC
Proteins were dialyzed into the ITC buffer (20 mM sodium phosphate, pH 6.5, 
and 150 mM NaCl). The thermodynamic parameters are determined 
using an isothermal titration calorimeter (iTC 200; MicroCal) at 25°C in 
20 mM sodium phosphate, pH 6.5, and 150 mM NaCl. For binding, 0.6 or 
2.2 mM recombinant human HEG1 C26 peptide (residues 1,356–1,381) 
was titrated from the syringe into the sample cell containing 40 µM KRIT1 
FERM domain WT or KRIT1 FERM (L717,721A) mutant protein, respec-
tively. Titration was performed by injecting volumes of 2.5 µl into the sam-
ple cell, during which the time between injections was 2 min. Further data 
evaluation was performed using the Origin program (MicroCal).
Protein crystallization
Human KRIT1 residues 417–736 were expressed and purified as de-
scribed previously (Liu et al., 2011). In brief, KRIT1 was cloned into the 
expression vector pLEICS-07 (Protex) and expressed in E. coli BL21 Star 
20% reversal of the dilated heart phenotype. Both WT and 
krit1(L714,718A) zebrafish krit1 cRNAs contained an N-terminal 
HA tag, and similar protein expression levels were confirmed 
by immunoprecipitation blot from zebrafish embryo lysates 
(Fig. 5 C). Silencing KRIT1 in HUVECs increased RhoA/Rho 
kinase signaling in HUVECs as judged by increased myosin 
light chain phosphorylation, and coexpressing an siRNA- 
resistant KRIT1 reversed this effect. In contrast, expressing 
siRNA-resistant KRIT1(L717,721A) did not reduce myosin 
light chain phosphorylation (Fig. 5, D and E; and Fig. S3). 
KRIT1(L717,721A) expression in the absence of KRIT1 silencing 
did not impair zebrafish heart development (not depicted) or 
increase RhoA/Rho kinase signaling in HUVECs (Fig. S4). 
Thus, the direct interaction between HEG1 and KRIT1 is im-
portant for zebrafish cardiovascular development and sup-
pression of RhoA signaling in EC.
Additional implications of the KRIT1–HEG1 
mode of interaction
Our data show that KRIT1 interacts with the HEG1 cytoplasmic 
tail in an unusual manner and establish a structural mechanism 
for HEG1 to recruit KRIT1, and potentially CCM2, to cell–cell 
junctions. The HEG1 cytoplasmic tail is 111 amino acids long 
and has little predicted secondary structure, and we show here 
that KRIT1 binds strongly at the C terminus. If fully extended, 
the HEG1 tail could reach distances of 30 nm, which could 
permit it to recruit KRIT1 from afar after KRIT1 release from 
intracellular sites such as microtubules by Rap1 (Béraud-Dufour 
et al., 2007). A common structural feature shared by PTB 
domains, such as KRIT1 F3, is the presence of a peptide 
binding pocket at the 5–1 interface, which often engages 
peptides containing NPxY/F motifs, and we note that when 
HEG1 is bound, this F3 peptide binding pocket remains acces-
sible (Fig. 2 B). Because KRIT1 is autoinhibited by the binding 
of KRIT1 N terminus NPXY/F motifs to F3 via this binding 
pocket (Béraud-Dufour et al., 2007; Francalanci et al., 2009), 
our results explain how HEG1 can efficiently bind to full-length, 
presumably autoinhibited, KRIT1 (Liu et al., 2011). Alterna-
tively, it is possible that the F3 subdomain of HEG1-bound 
KRIT1 can simultaneously engage other membrane proteins to 
create membrane microdomains at cell–cell junctions.
Materials and methods
Cell culture and transfection
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(Cellgro) supplemented with 10% FBS (Sigma-Aldrich), 1% nonessential 
amino acids, 1% l-glutamine, and 1% penicillin and streptomycin (all 
obtained from Invitrogen). HEK293 cells were transfected using Lipo-
fectamine Plus (Invitrogen) according to the manufacturer’s protocol. 
HUVECs (ScienCell) were maintained in EC medium with the manufac-
turer’s supplements (ScienCell). HUVECs were transfected using Nucleo-
fector II and HUVEC Nucleofector kit (both obtained from Lonza) according 
to the manufacturer’s protocol.
Antibodies, cDNAs, siRNA, and reagents
Monoclonal anti-HA and monoclonal anti-FLAG M2 antibodies (both 
obtained from Sigma-Aldrich) were used for immunoblotting at 1:4,000. 
Rabbit polyclonal anti-HA antibody (Takara Bio Inc.) was used for immuno-
precipitation. Mouse monoclonal anti-KRIT1 (15B2) and rabbit poly-
clonal anti-KRIT1 (6832) antibodies were developed using recombinant 
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camera [ImagEM-1K C9100-14; Hamamatsu Photonics]). Both 488- and 
560-nm lasers were used for imaging. All images were acquired for each 
experiment using the same camera sensor setting for all samples, and 
z-sliced images were exported as TIFF files using Volocity 6.0.1 software 
(PerkinElmer). All images were equally enhanced for display with contrast 
enhancement in Volocity 6.0.1. Images shown are representative of results 
from at least three independent experiments.
Differential scanning calorimetry
Differential scanning calorimetry experiments were performed at a scanning 
rate of 1 K/min under 3.0 atm of pressure using a differential scanning calo-
rimeter (N-DSC II; Calorimetry Sciences Corp.). Differential scanning calorim-
etry samples contained PBS, pH 7.4, and 1.0 mg/ml KRIT1 F123 or KRIT1 
F123(L717,721A).
Online supplemental material
Fig. S1 shows that KRIT1(L717,L721A) mutant protein is well folded 
and its expression in HEK293 cells is similar to WT. Fig. S2 shows that 
KRIT1(L717,721A) junctional localization was not restored by stabiliza-
tion of junctions by inhibition of Rho kinase. Fig. S3 quantifies the phospho–
myosin light chain increase caused by KRIT1 depletion in HUVECs. Fig. S4 
shows that KRIT1(L717,721A) did not increase RhoA/Rho kinase signal-
ing in HUVECs. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.201205109/DC1.
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(DE3) (Invitrogen). Recombinant His-tagged KRIT1 was purified by nickel-
affinity chromatography, the His tag was removed by cleavage with 
tobacco etch virus protease overnight, and the protein was further purified 
by cation-exchange chromatography. The protein concentration was as-
sessed using the A280 extinction coefficient of 45,090 M1 before dialysis 
into buffers. Crystals were grown at RT using the sitting-drop method by 
mixing equal volumes of protein complex and reservoir solution (2 + 2 µl). 
KRIT1 at a concentration of 11 mg/ml in 20 mM Tris, pH 8.0, 50 mM 
NaCl, and 2 mM DTT was mixed with an equimolar concentration of 
HEG1 C26 peptide (3 mM stock in water). The reservoir solution contained 
10% PEG 4000 and 100 mM citrate buffer, pH 4.0. The crystals were 
briefly transferred to reservoir solution containing 20% glycerol before 
freezing in liquid nitrogen.
Structure determination
Diffraction data for the KRIT1–HEG1 peptide complex were collected at 
European Synchrotron Radiation Facility microfocus beamline id23-2 
( = 0.873) and recorded on MAR 225 detectors (Marresearch). The data 
were processed and scaled using Mosflm and scala, respectively. Initial 
phases were determined with Phaser, and the model was optimized using 
cycles of manual refinement with Coot and maximum likelihood refinement 
in Refmac5—all part of the CCP4 software suite (Collaborative Computa-
tional Project, Number 4, 1994). The final Ramachandran plot shows 93.1% 
of residues in favored regions, 8.1% in allowed regions, and 1.3% in outlier 
region, as defined by PROCHECK (CCP4 suite). The crystal structure has 
been submitted to the Protein Data Bank with the accession no. 3U7D.
Zebrafish experiments
Tg(flk1:EGFP) Danio rerio (zebrafish) embryos were raised at 28.5°C. 
Embryos from natural matings were kept in 1-phenyl-2-thiourea (0.003%) 
to inhibit pigmentation and staged according to Kimmel et al. (1995). 
Zebrafish were housed in the University of California, San Diego animal 
facility, and experiments were performed in accordance with the guide-
lines of University of California, San Diego Institutional Animal Care and 
Use Committee.
Antisense MO oligonucleotides (San MO) targeting splice junc-
tions of krit1 (Liu et al., 2011), 5-TTGAAGTCTCACTTTTGTCTCCATG-3, 
or standard nontargeting control MO oligonucleotides (both obtained 
from Gene Tools) were injected into the yolks of one-cell-stage embryos 
at a dose of 1 ng. To rescue the enlarged heart phenotype caused by 
the krit1 MO, 1 ng krit1 MO and 400 pg cRNA encoding HA-tagged 
krit1 or krit1 (L714,718A) were coinjected into the one-cell-stage embryos. 
Transcription system (mMessage mMachine T7 ultra kit; Ambion) was used 
to prepare cRNAs. 48-hpf live embryos were mounted laterally in 1.2% 
agarose, and images were acquired using a fluorescence imaging system 
(4×/0.13 NA objective; BX40; Olympus). Images were acquired for each 
experiment using the same  setting for all examples, and images from 
each experiment were equally enhanced for display with brightness/
contrast adjustment using ImageJ software (National Institutes of Health).
Total zebrafish embryonic lysates from 20 injected embryos were used 
for immunoprecipitation. Rabbit anti-HA tag antibody was used for immuno-
precipitation, and mouse anti-HA tag antibody was used for immunoblotting.
Immunofluorescence
For KRIT1 subcellular localization, HUVECs were transfected with the in-
dicated HA-tagged KRIT1 WT or KRIT1(L717,721A) mutant and plated 
on fibronectin-coated glass coverslips at 90% confluence. HA-KRIT1–
transfected cells were grown for 24 h before fixation. In some experi-
ments, HUVECs were transfected with anti-KRIT1 siRNA in the presence 
or absence of cDNAs encoding either WT or mutant KRIT1, and phos-
phorylation of myosin light chain was assessed by immunoblotting as 
previously described (Stockton et al., 2010). Cells were fixed with 3.7% 
paraformaldehyde for 30 min at RT, permeabilized for 5 min with 0.2% 
Triton X-100, and blocked for 1 h with 10% normal goat serum (Sigma-
Aldrich) in PBS, pH 7.4. Cells were probed with mouse anti-HA antibody 
(Covance) in PBS with 10% normal goat serum together with rabbit anti–
VE-cadherin XP antibody (Cell Signaling Technology) for 3 h at RT in a 
humidified chamber. Coverslips were washed with PBS with 0.01% Triton 
X-100 (PBST) and then incubated with the indicated Alexa Fluor 488–
labeled anti–mouse IgG and Alexa Fluor 568–labeled anti–rabbit IgG 
(both purchased from Invitrogen) at 1:1,000 for 1 h at RT. Coverslips were 
washed in PBST and PBS and then mounted in ProLong gold (Invitrogen). 
Cells were imaged at RT using a confocal microscopy system (spinning-disk 
confocal [UltraVIEW VoX; PerkinElmer] with an inverted microscope [IX81], a 
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